Anterogen Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seoul Korea, Republic of (2000)

Organization Overview

First Clinical Trial
2004
NCT00992147
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Anterogen Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 2)

Consciousness Disorders (Phase 3)

Crohn Disease (Phase 1)

Depression (Phase 3)

Diabetic Foot (Phase 3)

Fecal Incontinence (Phase 1)

Fistula (Phase 3)

Foot Ulcer (Phase 3)

Tennis Elbow (Phase 2)

Ulcer (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 7